|View printer-friendly version|
Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration
February 9, 2018 at 6:45 AM EST
-Companies to Evaluate Novel Bispecific Immuno-Oncology Agents that Combine Pieris’ Anticalin Technology with Select Seattle Genetics Cancer-Targeted Antibodies-
The collaboration leverages the expertise and core technologies of both
companies to develop novel Antibody-Anticalin fusion proteins. Pieris’
proprietary suite of agonistic costimulatory Anticalin proteins, when
fused to a tumor-targeting antibody, can activate the immune system
preferentially in the tumor microenvironment.
“As the industry leader in ADCs, we bring deep expertise in targeted
cancer therapy development to this collaboration with Pieris,” said
Under the terms of the agreement,
“Pieris was the first company to bring a tumor-targeted costimulatory
bispecific to patients with PRS-343, and we are looking forward to
broadening our bispecific pipeline through this alliance.
About Anticalin® Therapeutics:
Anticalin® proteins are derived from lipocalins, small human proteins that naturally bind, store and transport a wide spectrum of molecules. Anticalin® proteins feature the typical four-loop variable region and a rigidly conserved beta-barrel backbone of lipocalins, which, together, form a shapeable cup-like binding pocket. Proprietary to Pieris, Anticalin® proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin® protein to treat uncontrolled asthma and a half-life-optimized Anticalin® protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.
For more information visit www.pieris.com.
Seattle Genetics is an innovative biotechnology company dedicated to improving the lives of people with cancer through novel antibody-based therapies. The company’s industry-leading antibody-drug conjugate (ADC) technology harnesses the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells. Seattle Genetics commercializes ADCETRIS® (brentuximab vedotin) for the treatment of several types of CD30-expressing lymphomas. The company is also advancing a robust pipeline of novel therapies for solid tumors and blood-related cancers designed to address significant unmet medical needs and improve treatment outcomes for patients. More information can be found at www.seattlegenetics.com and follow @SeattleGenetics on Twitter.
Pieris Forward Looking Statements Disclaimer:
This press release contains forward-looking statements as that term is
defined in Section 27A of the Securities Act of 1933 and Section 21E of
the Securities Exchange Act of 1934. Statements in this press release
that are not purely historical are forward-looking statements. Such
forward-looking statements include, among other things, references to
novel technologies and methods; our business and product development
plans; the timing and progress of our studies, including the timing of
enrollment and dosing of PRS-343 patients and PRS-060 healthy subjects,
the enrollment of patients in the PRS-080 multi-dose trial; our
liquidity and ability to fund our future operations; our ability to
achieve certain milestones and receive future milestone or royalty
payments; or market information. Actual results could differ from those
projected in any forward-looking statements due to numerous factors.
Such factors include, among others, our ability to raise the additional
funding we will need to continue to pursue our business and product
development plans; the inherent uncertainties associated with developing
new products or technologies and operating as a development stage
company; our ability to develop, complete clinical trials for, obtain
approvals for and commercialize any of our product candidates, including
our ability to recruit and enroll patients in our studies; our ability
to address the requests of the
Seattle Genetics Forward Looking Statements Disclaimer:
Certain of the statements made in this press release are forward
looking, such as those, among others, relating to the research,
development, and therapeutic and commercial potential of Anticalin-based
products. Actual results or developments may differ materially from
those projected or implied in these forward-looking statements. Factors
that may cause such a difference include the possibility that the
referenced product candidates may not be feasible to develop, may not
show utility in treating cancer, may not have the desired activity or
may be associated with adverse events that limit their use in which case
Contacts at Pieris: